


The ROC analyses for both the RAMP® NT-proBNP and Roche Elecsys proBNP tests for the clinical trial population are shown below. The additional 159 patients without results from the Elecsys system were excluded from this comparison. The area under the curve (AUC) for both the RAMP® NT-proBNP test and Elecsys proBNP test is 0.87.



NYHA Functional Classification

The 299 subjects diagnosed with heart failure were evaluated using the RAMP® NT-proBNP test. The descriptive statistics for NT-proBNP concentrations are presented according to NYHA Functional Classification in the table below.

NYHA Class	n	Mean	SD	Median	95 th Percentile
I	58	1686	3161	832	5560
II	91	2831	4356	1479	8104
III	84	5737	5939	3608	20177
IV	66	8308	7090	6628	>22000
Total	299	3133	3755	1735	11373

Overall Incidence of Disease

The overall incidence of disease in the presenting population (n=858) included 38% (323) subjects with hypertension, 24% (208) who presented with shortness of breath, 18% (152) with diabetes, 12% (99) with pulmonary disorders, 10% (84) with coronary disease, 7% (56) with atrial fibrillation, 4% (31) with renal failure, 34% (292) were healthy, and the remainder had diagnoses not believed to be cardiac related (hepatitis, HIV, cancer, etc.).



The circulating NT-proBNP concentration was determined in 858 individuals with and without HF. The HF subjects included those with prior established heart failure that were not acutely destabilized at the time of enrollment (and thus similar to those who might be tested in the outpatient setting). Subjects (n=17) for whom the measured NT-proBNP level was greater than 22,000 ng/L are excluded. The descriptive statistics for the Non-HF (with and without co-morbidities) and the HF groups are presented in the following tables:

Parameter	Non-HF			HF		
	≤75	>75	All Ages	≤75	>75	All Ages
n	340	30	370	124	65	559
Mean	133	450	159	871	1013	349
SD	671	811	688	3445	1525	996
Median	25	88	28	186	512	66
95 th Percentile	216	2447	451	2463	3986	1544
% < 125 ng/L	84	-	-	44	-	-
% < 450 ng/L	-	74	-	-	48	-

Parameter	Non-HF		
	≤75	>75	All
n	203	80	283
Mean	3133	4970	3652
SD	3755	5186	4280
Median	1735	3301	2040
95 th Percentile	11373	19005	12800
% > 125 ng/L	89	-	-
% > 450 ng/L	-	100	-

- Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004;6:257-260.
- Richards AM, Nicholls GM, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: New hormonal predictors of left ventricular function and prognosis after myocardial infarction. Circ. 1998;97:1921-1929.
- Rademaker MT, and Richards MA. Cardiac natriuretic peptides for cardiac health. Clin Sci. 2005;108:23-36.

- Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948-954.
- Baggish AL, Cameron R, Anwaruddin S, et al. A clinical and biochemical critical pathway for the evaluation of patients with suspected acute congestive heart failure. The proBNP investigation of dyspnea in the emergency department (PRIDE) algorithm. Crit Path Cardiol. 2004;3:171-176.
- James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a global utilization of strategies to open occluded arteries (GUSTO)-IV substudy. Circ. 2003;108:275-81.
- Jernberg T, Stridsberg M, Venge P, et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002;40:437-45.
- Fisher C, Berry C, Blue L, et al. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart. 2003;89:879-81.
- Schnabel R, Rupprecht HJ, Lackner KJ, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: Results from the AtheroGene study. Eur Heart J. 2005;26:241-249.
- Kragelund C, Groenning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Eng J Med. 2005;352:666-675.
- Ndrepepa G, Braun S, Niemoller K, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circ. 2005;112:2102-2107.



If you have any questions regarding the use of this product please contact Response Biomedical Corp. Technical Support:


- Within US or Canada (+1.866.525.7267)
- Outside US or Canada (+1.604.219.6119)
- By email at info@responsebiomedical.com



RESPONSE BIOMEDICAL



JANT PHARMACAL CORPORATION
Laboratory & Point of Care Diagnostics



2020-02, V 1.5, English

C1103

RAMP® is a registered trademark of Response Biomedical Corp. ProClin® is a registered trademark of Rohm and Haas Company. Other trademarks are the property of their respective owners.

